CelLBxHealth PLC, a cancer diagnostics firm, reaffirmed its revenue guidance of at least £2.1 million for 2026, representing a 50% increase from 2025. This announcement comes as the company searches for a new chief executive, with current executive chairman Jan Groen assuring investors that the leadership team can maintain operations without disruption. The company's technology, which captures live circulating tumour cells from blood, offers a significant commercial opportunity by addressing limitations of competing ctDNA tests. The board has started the CEO recruitment process and will provide updates to shareholders in due course.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ERock, Inc. received a buy rating due to its innovative modular natural-gas power systems that help data centers avoid long waits for permanent grid power. The company has a strong $1.3 billion backlog supported by customer deposits, providing clear ...
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
BMW is recalling 29,119 plug-in hybrid sedans due to a potential fire risk caused by corrosion in the engine starter's electrical relay. This defect can lead to a short circuit and overheating even when the vehicle is parked with the ignition off. Th...
The Fidelity Fundamental Large Cap Core ETF (FFLC) provides an actively managed alternative to traditional S&P 500 index funds by emphasizing risk-adjusted returns and fundamental company strength. FFLC excludes companies with high valuations and low...
